From: Risk factors affecting outcome of rhino-orbital-cerebral mucormycosis in COVID-19 patients
 | Alive | Death | Test value | p-value | Sig. |
---|---|---|---|---|---|
No. = 24 | No. = 9 | ||||
Fever | 7 (29.2%) | 7 (77.8%) | 6.332* | 0.012 | S |
Facial numbness | 15 (62.5%) | 5 (55.6%) | 0.132* | 0.716 | NS |
Facial swelling | 13 (54.2%) | 6 (66.7%) | 0.419* | 0.518 | NS |
Headache | 16 (66.7%) | 7 (77.8%) | 0.383* | 0.536 | NS |
Facial pain | 16 (66.7%) | 7 (77.8%) | 0.383* | 0.536 | NS |
Rhinorrhea, blood stained | 7 (29.2%) | 4 (44.4%) | 0.688* | 0.407 | NS |
Orbital swelling | 15 (62.5%) | 8 (88.9%) | 2.158* | 0.142 | NS |
Ophthalmoplegia | 10 (41.7%) | 8 (88.9%) | 5.887* | 0.015 | S |
Visual loss | 9 (37.5%) | 7 (77.8%) | 4.251* | 0.039 | S |
Disturbed conscious | 4 (16.7%) | 4 (44.4%) | 2.750* | 0.097 | NS |
Motor or sensory weakness (stroke) | 4 (16.7%) | 2 (22.2%) | 0.136* | 0.712 | NS |
First presentation | |||||
 Eye swelling | 5 (62.5%) | 0 (0.0%) | 2.250* | 0.325 | NS |
 Disturbed conscious | 2 (25.0%) | 1 (100.0%) | |||
 Facial swelling | 1 (12.5%) | 0 (0.0%) | |||
Intranasal necrosis | 21 (87.5%) | 8 (88.9%) | 0.012* | 0.913 | NS |
Palatal necrosis | 13 (54.2%) | 6 (66.7%) | 0.419* | 0.518 | NS |
Proptosis | 8 (33.3%) | 5 (55.6%) | 1.354* | 0.245 | NS |
Cavernous sinus thrombosis | 11 (45.8%) | 7 (77.8%) | 2.694* | 0.101 | NS |
Facial skin necrosis | 0 (0.0%) | 2 (22.2%) | 5.677* | 0.017 | S |
Cranial nerves involvement | |||||
 Negative | 18 (75.0%) | 9 (100.0%) | 2.750* | 0.097 | NS |
 Facial | 6 (25.0%) | 0 (0.0%) |